Compare · AKAN vs DFTX
AKAN vs DFTX
Side-by-side comparison of Akanda Corp. (AKAN) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKAN and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 1471.4x AKAN ($3.1M).
- Over the past year, AKAN is down 97.5% and DFTX is up 144.3% - DFTX leads by 241.8 points.
- DFTX has been more active in the news (8 items in the past 4 weeks vs 2 for AKAN).
- DFTX has more recent analyst coverage (8 ratings vs 0 for AKAN).
PerformanceAKAN-97.51%DFTX+144.26%
2025-10-20+0.00%2026-10-16
- Company
- Akanda Corp.
- Definium Therapeutics Inc.
- Price
- -
- -
- Market cap
- $3.1M
- $4.60B
- 1M return
- -57.73%
- -17.01%
- 1Y return
- -97.51%
- +144.26%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 2
- 8
- Recent ratings
- 0
- 8
AKAN
Akanda Corp.
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and internationally. It intends to supply cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
Latest AKAN
- SEC Form F-1 filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- First Towers & Fiber Corp. Delivers First Cash Flow from New 200 KM Fiber Network, Eyes Expansion with Client
- SEC Form 6-K filed by Akanda Corp.
- Akanda's First Towers & Fiber Increases Recurring Revenue with Completion of 200 KM Fiber Network
- SEC Form 6-K filed by Akanda Corp.
- Coloured Ties Capital Announces Proposed Share Consolidation
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.